ATE357236T1 - Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs - Google Patents

Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs

Info

Publication number
ATE357236T1
ATE357236T1 AT03751032T AT03751032T ATE357236T1 AT E357236 T1 ATE357236 T1 AT E357236T1 AT 03751032 T AT03751032 T AT 03751032T AT 03751032 T AT03751032 T AT 03751032T AT E357236 T1 ATE357236 T1 AT E357236T1
Authority
AT
Austria
Prior art keywords
gemcitabine
treatment
cancer
appropriate
combined
Prior art date
Application number
AT03751032T
Other languages
English (en)
Inventor
Alan Barge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE357236T1 publication Critical patent/ATE357236T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03751032T 2002-10-09 2003-10-06 Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs ATE357236T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0223380.7A GB0223380D0 (en) 2002-10-09 2002-10-09 Combination therapy

Publications (1)

Publication Number Publication Date
ATE357236T1 true ATE357236T1 (de) 2007-04-15

Family

ID=9945538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03751032T ATE357236T1 (de) 2002-10-09 2003-10-06 Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs

Country Status (22)

Country Link
US (2) US20060009418A1 (de)
EP (1) EP1551409B1 (de)
JP (2) JP5416328B2 (de)
KR (1) KR101098061B1 (de)
CN (1) CN100363004C (de)
AT (1) ATE357236T1 (de)
AU (1) AU2003269253B2 (de)
BR (1) BR0315088A (de)
CA (1) CA2501651C (de)
CY (1) CY1106601T1 (de)
DE (1) DE60312715T2 (de)
DK (1) DK1551409T3 (de)
ES (1) ES2282656T3 (de)
GB (1) GB0223380D0 (de)
IL (1) IL167633A (de)
MX (1) MXPA05003595A (de)
NO (1) NO330601B1 (de)
NZ (1) NZ538999A (de)
PT (1) PT1551409E (de)
SI (1) SI1551409T1 (de)
WO (1) WO2004032937A1 (de)
ZA (1) ZA200502753B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
SI1474420T1 (sl) 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (de) * 2003-07-10 2010-08-25 AstraZeneca AB Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
KR20080031029A (ko) * 2005-07-06 2008-04-07 아스트라제네카 아베 Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
JPWO2008088088A1 (ja) 2007-01-19 2010-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 膵癌治療用組成物
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN106727657A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗糖尿病的西药组合物及应用
CN106619688A (zh) * 2016-12-27 2017-05-10 郑州郑先医药科技有限公司 一种治疗糖尿病的药物组合物及应用
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184365B1 (de) * 1984-12-04 1993-08-04 Eli Lilly And Company Tumorbehandlung bei Säugetieren
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6953679B2 (en) * 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (de) * 2003-07-10 2010-08-25 AstraZeneca AB Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
KR20080031029A (ko) * 2005-07-06 2008-04-07 아스트라제네카 아베 Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20100212978A1 (en) * 2009-02-23 2010-08-26 Wen-Hung Huang Bicycle with two operation molds

Also Published As

Publication number Publication date
EP1551409B1 (de) 2007-03-21
BR0315088A (pt) 2005-08-16
CN100363004C (zh) 2008-01-23
KR101098061B1 (ko) 2011-12-26
DE60312715D1 (de) 2007-05-03
US20060009418A1 (en) 2006-01-12
HK1078771A1 (en) 2006-03-24
ES2282656T3 (es) 2007-10-16
DK1551409T3 (da) 2007-06-11
JP2011088921A (ja) 2011-05-06
GB0223380D0 (en) 2002-11-13
AU2003269253A1 (en) 2004-05-04
NO330601B1 (no) 2011-05-23
EP1551409A1 (de) 2005-07-13
SI1551409T1 (sl) 2007-08-31
AU2003269253B2 (en) 2007-04-05
JP2006504723A (ja) 2006-02-09
DE60312715T2 (de) 2007-12-06
PT1551409E (pt) 2007-05-31
WO2004032937A1 (en) 2004-04-22
MXPA05003595A (es) 2005-06-03
NO20051575L (no) 2005-04-25
CN1703223A (zh) 2005-11-30
CA2501651C (en) 2011-02-15
NZ538999A (en) 2008-02-29
KR20050055070A (ko) 2005-06-10
JP5416328B2 (ja) 2014-02-12
CA2501651A1 (en) 2004-04-22
US20100120708A1 (en) 2010-05-13
IL167633A (en) 2013-03-24
ZA200502753B (en) 2006-03-29
CY1106601T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE357236T1 (de) Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs
ATE478671T1 (de) Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
NO20082567L (no) Kombinasjon av ZD6474 og pemetrexed
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
PL1653964T3 (pl) Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1551409

Country of ref document: EP